news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

According to the AI ​​Express of Meijing, an investor asked on the investor interaction platform: Mr. Secretary, EyePoint Pharmaceuticals recently issued an announcement announcing the issuance of new shares at a price of US$13.75 per share. This additional issuance raised a total of approximately US$115.4 million and will be used to support its key projects, including the advancement of the Phase III clinical trial of EYP-1901 and other research and development activities. Did Beida Pharmaceutical participate in this additional issuance of shares to further strengthen cooperation and accelerate the progress of cooperative projects?

Beida Pharmaceuticals (300558.SZ) stated on the investor interaction platform on August 16 that the company signed an "Exclusive License Agreement" with EyePoint Pharmaceuticals, Inc. through its holding subsidiary Equinox Sciences, LLC in February 2020, exclusively authorizing EyePoint to develop voronib by local injection to treat eye diseases such as wet age-related macular degeneration (wAMD) (i.e., the EYP-1901 project), and signed an "Expanded License Agreement" with EyePoint in 2022 to obtain the exclusive right to develop and commercialize the EYP-1901 project in China (including Hong Kong, Macau and Taiwan). At present, the EYP-1901 project is expected to conduct Phase III clinical trials in the United States in the second half of the year, and its domestic application for clinical trials of wAMD indication drugs has recently been approved. In addition to the above cooperation, the company has not participated in EyePoint's private placement plan and does not hold EyePoint shares.

(Reporter Cai Ding)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be solely responsible for any risks involved in your actions.

Daily Economic News